GNOM


Genomics & Biotechnology ETF

Reasons to Consider GNOM

High Growth Potential

Manufacturing genomic medicines is cumbersome, but new techniques using donated cells are more scalable and could slash production costs by 95%, potentially facilitating broader adoption.1

Structural Tailwinds

Recent regulatory approvals have helped genomic medicines gain momentum. Sales of genomic medicines are forecast to increase at a 47% compound annual growth rate from 2022-2028.2

Targeted Exposure

GNOM provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

1International Society for Cell and Gene Therapy, Feb 2019
2Evaluate Pharma, Nov 2023

Key Information As of 05/28/24

Inception Date 04/05/19
Total Expense Ratio 0.50%
Net Assets $94.30 million
NAV $10.34
Fact Sheet View the document

ETF Summary

The Global X Genomics & Biotechnology ETF (GNOM) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

ETF Objective

The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.

Trading Details As of 05/28/24

Ticker GNOM
Bloomberg Index Ticker SOLGNOM
CUSIP 37954Y434
ISIN US37954Y4347
Primary Exchange Nasdaq
Shares Outstanding 9,120,000
Number of Holdings 41
30-Day Median Bid-Ask Spread 0.10%

Distributions As of 05/28/24

30-Day SEC Yield -0.18%
Distribution Frequency Semi-Annually

ETF Prices As of 05/28/24

NAV $10.34 Daily Change -$0.22 -2.08%
Market Price $10.32 Daily Change -$0.24 -2.27%

Performance History

As of recent
(03/31/24)
As of recent
(03/31/24)
Fund NAV Market Price Index
1 Year -7.57% -7.63% -6.37%
3 Years -20.26% -20.29% -19.88%
Since Inception -5.73% -5.35% -5.25%
1 Year -19.59% -19.66% -18.48%
3 Years -24.08% -24.12% -23.70%
5 Years -7.15% -7.19% -6.68%
Since Inception -8.26% -7.92% -7.79%
Year-to-Date -1.82% -1.56% -1.55%
1 Month -5.41% -5.01% -5.23%
3 Months -1.82% -1.56% -1.55%
Since Inception -25.53% -24.01% -23.62%
Year-to-Date -14.87% -14.79% -14.57%
1 Month -13.29% -13.44% -13.22%
3 Months -8.46% -8.37% -8.24%
Since Inception -35.43% -34.22% -33.72%

Performance is shown on a total return basis (i.e., with gross income reinvested, where applicable). Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance, when observed, is unusual and investors should not expect such performance to be repeated.

Top Holdings As of 05/28/24

Net Assets (%) Ticker Name SEDOL Market Price ($) Shares Held Market Value ($)
5.43 MRNA MODERNA INC BGSXTS3 153.20 33,448 5,124,233.60
4.83 TECH BIO-TECHNE CORP BSHZ3Q0 79.39 57,315 4,550,237.85
4.62 NTRA NATERA INC BYQRG48 109.57 39,790 4,359,790.30
4.16 A AGILENT TECHNOLOGIES INC 2520153 148.21 26,481 3,924,749.01
4.12 BNTX BIONTECH SE-ADR BK6H543 94.10 41,331 3,889,247.10
4.08 NTLA INTELLIA THERAPEUTICS INC BYZM6C2 22.72 169,364 3,847,950.08
4.03 ALNY ALNYLAM PHARMACE B00FWN1 150.06 25,319 3,799,369.14
4.00 QGEN QIAGEN N.V. BMGBZP0 43.02 87,690 3,772,423.80
3.97 ARWR ARROWHEAD PHARMA BYQBFJ8 23.92 156,333 3,739,485.36
3.82 MYGN MYRIAD GENETICS INC 2614153 23.32 154,621 3,605,761.72
3.81 CRSP CRISPR THERAPEUTICS AG BDHF4K6 54.84 65,427 3,588,016.68
3.58 RNA AVIDITY BIOSCIENCES INC BMWHPY1 26.32 128,257 3,375,724.24
3.56 LEGN LEGEND BIOTECH CORP-ADR BMX9K07 41.68 80,606 3,359,658.08
3.52 SRPT SAREPTA THERAPEUTICS INC B8DPDT7 113.33 29,303 3,320,908.99
3.43 RARE ULTRAGENYX PHARM BJ62Z18 39.34 82,227 3,234,810.18
3.35 RCKT ROCKET PHARMACEU BDFKQ07 20.94 151,060 3,163,196.40
3.30 ILMN ILLUMINA INC 2613990 105.03 29,633 3,112,353.99
3.19 TXG 10X GENOMICS INC-CLASS A BKS3RS7 22.70 132,304 3,003,300.80
3.15 BMRN BIOMARIN PHARMAC 2437071 74.43 39,924 2,971,543.32
3.13 BEAM BEAM THERAPEUTICS INC BK6L288 24.22 121,933 2,953,217.26
3.02 VCYT VERACYTE INC BFTWZY0 21.45 132,699 2,846,393.55
2.73 1548 HK GENSCRIPT BIOTECH CORP BD9Q2J2 1.32 1,946,618 2,572,062.96
2.14 VRTX VERTEX PHARM 2931034 446.88 4,521 2,020,344.48
1.83 GILD GILEAD SCIENCES INC 2369174 63.94 26,918 1,721,136.92
1.82 VIR VIR BIOTECHNOLOGY INC BK4PZ38 10.73 159,971 1,716,488.83
1.78 SANA SANA BIOTECHNOLOGY INC BMFJJ97 7.80 215,277 1,679,160.60
1.50 CDNA CAREDX INC BP3YM74 16.15 87,475 1,412,721.25
1.25 RGNX REGENXBIO INC BZ0G875 14.96 79,074 1,182,947.04
0.92 PACB PACIFIC BIOSCIEN B4N8MH9 1.88 461,771 865,820.63
0.82 FLGT FULGENT GENETICS INC BYQBFQ5 21.62 35,637 770,471.94
0.82 EDIT EDITAS MEDICINE INC BZ8FPH3 5.32 144,497 768,724.04
0.61 LYEL LYELL IMMUNOPHARMA INC BN6MB18 2.75 209,694 576,658.50
0.59 4974 JP TAKARA BIO INC B03ML21 6.57 84,210 553,543.37
0.54 VERV VERVE THERAPEUTICS INC BNKGXX2 5.24 97,339 510,056.36
0.48 ALLO ALLOGENE THERAPEUTICS INC BFZNYB7 2.43 187,647 455,982.21
0.44 CRBU CARIBOU BIOSCIENCES INC BNYJR68 2.99 139,370 416,716.30
0.39 PSTX POSEIDA THERAPEUTICS INC BJ4SF41 2.86 129,769 371,139.34
0.39 QURE UNIQURE NV BJFSR88 4.72 77,457 365,597.04
0.38 TSVT 2SEVENTY BIO INC BMTXV88 4.27 84,699 361,664.73
0.34 BLUE BLUEBIRD BIO INC BBFL7S1 0.94 336,055 315,925.31
0.09 CASH 1.00 85,325 85,324.82
0.07 E SCILEX HOLDING RESTRICTED 9A80I96 0.27 226,071 61,039.05
0.00 JAPANESE YEN 0.01 -1 -0.01
-0.03 OTHER PAYABLE & RECEIVABLES 1.00 -28,748 -28,748.09
Holdings are subject to change. "Cash" denotes U.S. dollars.

Exposure As of 04/30/24

Industry Weight (%)
Biotechnology 75.2
Medical Specialties 11.1
Medical/Nursing Services 9.7
Pharmaceuticals: Major 3.3
Miscellaneous Commercial Services 0.6
Other 0.1

Source: new windowAltaVista Research, LLC

Country Weight (%)
United States 78.3
Italy 7.5
Switzerland 4.6
Netherlands 4.1
Germany 3.2
China 1.8
Japan 0.6

Source: new windowAltaVista Research, LLC

All Sector, Industry and Geographic breakdowns, where provided, are based on equity positions held by the ETF and exclude cash, currencies, and other holdings.

ETF Characteristics As of 05/28/24

Return on Equity -16.60%
Weighted Avg. Market Cap 16,496 M
2023 2024
Price-to-earnings -14.61 -17.35
Price-to-book value 2.63 3.16

Source: new windowAltaVista Research, LLC

ETF Risk Stats As of 04/30/24

Versus Beta
S&P 500 1.22
NASDAQ-100 1.00
MSCI EAFE 1.09
MSCI Emg. Mkts 0.93
Standard Deviation 30.70%

Source: new windowAltaVista Research, LLC

ETF Research

View More Related Research

Investing involves risk, including the possible loss of principal. The investable universe of companies in which GNOM may invest may be limited. The Fund invests in securities of companies engaged in Genomics, Healthcare and Biotechnology sectors. These sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from social, economic or political instability in other nations. GNOM is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares did not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.